Cassava Sciences Inc vs Trade Desk Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Trade Desk Inc trades at $12.4 (market cap $5.72B). The key difference: Trade Desk Inc is far larger — about 145.2× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 14,380,236). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Trade Desk Inc for 72 Days on average.
| FLNA | TTD | |
|---|---|---|
Market Cap | $39.40M | $5.72B |
Volume | 759,018 | 14,380,236 |
Sector | Health | Media |
52-Week High | $4.64 | $54.13 |
52-Week Low | $0.68 | $11.92 |
Typical Hold Time | 37 Days | 72 Days |
Enterprise Value | -$43.28M | $4.66B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
TTD trades at $12.34, down 3.52% today and 68% year-to-date, reflecting bearish technical signals and recent earnings misses. Revenue grew to $2.90B in 2025 with a 15.3% net margin, but 2026 guidance indicates slowing growth. The stock faces pressure from competition and index removal flows, with analyst consensus at a $14.72 price target amid mixed sentiment.
Outlook remains cautious due to competitive threats and slowing revenue growth, though valuation ratios appear low. Key risks include execution challenges and macroeconomic headwinds, while potential upside hinges on market share retention and cost management improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →